Therapeutic Drug Monitoring of Sunitinib and Pazopanib in Advanced or Metastatic Renal Cell Carcinoma

Summary

This pilot study is an open-label interventional study, prospective, non-comparative, sequential (two stages), national, multicenter study. Patients starting therapy with sunitinib or pazopanib as standard first line treatment for advanced or metastatic renal cell carcinoma will enter the study in one of the two cohorts (115 patients will be treated by sunitinib and 99 patients will be treated by pazopanib). The purpose of this study is to examine the feasibility of sunitinib and pazopanib dose individualisation based on therapeutic drug monitoring (TDM) and to assess the benefit of this approach in terms of tolerance and efficacy compared with the current empirical method based only on tolerance observation.

Timeline

Start

2015-11-17

Primary completion

2020-01-16

Completion

2020-01-16

Publications

• Results Le Louedec F, Morvan L, Mourey L, Maillard M, Vachoux C, Yakoubi M, Tosi D, Gravis G, Roubaud G, Thuillier F, Boyle H, Thomas F, White-Koning M, Puisset F, Chatelut E. Model-Informed Precision Dosing of Protein Kinase Inhibitors: Evaluation of Model-Averaging and Flattened Priors Methods. Clin Pharmacokinet. 2026 May;65(5):681-692. doi: 10.1007/s40262-026-01628-2. Epub 2026 Mar 9.

Drugs

Indications